Literature DB >> 23247833

Propranolol for hemangiomas.

Mahmudul Hasan1, Matiur Rahman, Shafiqul Hoque, A K M Zahid Hossain, Lubna Khondker.   

Abstract

OBJECTIVE: Hemangiomas are the most common benign soft tissue tumors occurring in 5-10 % of children at around the age of 1 year and of them 10 % are associated with significant morbidity and entail medical attention. In this study, efficacy and adverse effects of the drug propranolol were observed on hemangiomas.
METHODS: Oral propranolol was given to 36 children at a dose of 3 mg/kg/day in three divided doses. Blood pressure and heart rate were recorded during the first 3 h of treatment. Treatment was continued at home and the children were re-evaluated at monthly interval. Photographs were taken in pre- and post-treatment phages and changes of hemangiomas were measured with visual analog scale.
RESULTS: Immediate effects on color and growth were noted in all cases that were especially dramatic in cases of extensive lesions. Clinical evidence of regression was seen within 30 days in all cases and completely regressed within 7 months. Mean duration of treatment was 4.1 months.
CONCLUSION: Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247833     DOI: 10.1007/s00383-012-3220-5

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  3 in total

1.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

2.  Infantile hemangiomas with unusually prolonged growth phase: a case series.

Authors:  Heather A Brandling-Bennett; Denise W Metry; Eulalia Baselga; Anne W Lucky; Denise M Adams; Maria R Cordisco; Ilona J Frieden
Journal:  Arch Dermatol       Date:  2008-12

3.  Propranolol for severe infantile hemangiomas: follow-up report.

Authors:  Véronique Sans; Eric Dumas de la Roque; Jérôme Berge; Nicolas Grenier; Franck Boralevi; Juliette Mazereeuw-Hautier; Dan Lipsker; Elisabeth Dupuis; Khaled Ezzedine; Pierre Vergnes; Alain Taïeb; Christine Léauté-Labrèze
Journal:  Pediatrics       Date:  2009-08-10       Impact factor: 7.124

  3 in total
  3 in total

Review 1.  Beta blockers: an innovation in the treatment of infantile hemangiomas.

Authors:  Shehla Admani; Stephanie Feldstein; Ernesto M Gonzalez; Sheila Fallon Friedlander
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

Review 2.  Infantile Hemangioma: A Brief Review.

Authors:  Madalina Bota; Gheorghe Popa; Cristina Blag; Alexandru Tataru
Journal:  Clujul Med       Date:  2015-01-28

3.  Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol.

Authors:  Ebrahim Salehifar; Shima Ebrahim; Mohammad-Reza Shiran; Fatemeh Faramarzi; Hossein Askari Rad; Razieh Avan; Asadollah Mohseni Kiasari; Pouneh Ebrahimi
Journal:  Adv Pharm Bull       Date:  2017-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.